Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant emerged in November 2021 and consists of several mutations within the spike. We use serum from mRNA-vaccinated individuals to measure neutralization activity against omicron in a live-virus assay. At 2-4 weeks after a primary series of vaccinations, we observe a 30-fold reduction in neutralizing activity against omicron. Six months after the initial two-vaccine doses, sera from naive vaccinated subjects show no neutralizing activity against omicron. In contrast, COVID-19-recovered individuals 6 months after receiving the primary series of vaccinations show a 22-fold reduction, with the majority of the subjects retaining neutralizing antibody responses. In naive individuals following a booster shot (third dose), we observe a 14-fold reduction in neutralizing activity against omicron, and over 90% of subjects show neutralizing activity. These findings show that a third dose is required to provide robust neutralizing antibody responses against the omicron variant.
Keywords: B.1.1.529; Omicron; Omicron variant; SARS-CoV-2; antibody; booster dose; live-virus; mRNA vaccines; neutralization assay; vaccine induced immunity.
【저자키워드】 SARS-CoV-2, antibody, omicron, mRNA vaccines, Neutralization assay, Omicron variant, B.1.1.529, booster dose, live-virus, vaccine induced immunity., 【초록키워드】 Vaccine, coronavirus, vaccination, Mutation, Immunity, antibody, neutralization, severe acute respiratory syndrome Coronavirus, omicron, mRNA vaccines, serum, Neutralizing activity, Neutralization assay, mRNA, sera, Omicron variant, respiratory, booster dose, Neutralizing antibody response, booster, Vaccinations, dose, reduction, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, subject, naïve individuals, individual, neutralization activity, neutralizing antibody responses, doses, robust, initial, observé, required, receiving, majority, reduction in, 【제목키워드】 mRNA-1273, BNT162b2 mRNA vaccine, reduced, the SARS-CoV-2,